卡瑞利珠单抗联合培美曲塞和卡铂一线治疗晚期非鳞状非小细胞肺癌伴脑转移的疗效、安全性与健康相关生活质量(CAP-BRAIN):一项多中心、开放标签、单臂、2期研究
这项多中心单臂2期研究纳入45例初治晚期非鳞状非小细胞肺癌伴脑转移患者,接受卡瑞利珠单抗联合培美曲塞和卡铂一线治疗。在可评估疗效的40例患者中,颅内确认客观缓解率为52.5%,中位颅内无进展生存期7.6个月,中位总生存期21.0个月,≥3级治疗相关不良事件常见中性粒细胞减少和贫血,并观察到认知功能与生活质量改善趋势。
要点
- 可评估疗效患者颅内确认客观缓解率52.5%,全分析集46.7%。
- 中位颅内无进展生存期7.6个月,中位总生存期21.0个月。
- 常见≥3级治疗相关不良事件为中性粒细胞减少6例(13.3%)和贫血4例(8.9%)。
核心结论
- 卡瑞利珠单抗联合培美曲塞和卡铂一线治疗非鳞状非小细胞肺癌伴脑转移患者具有活性,毒性可控,并改善认知功能与生活质量。
研究设计与样本
- 多中心、开放标签、单臂、2期试验(NCT04211090),在中国七家医院开展。
- 纳入45例初治转移性非鳞状非小细胞肺癌伴无症状或经脱水治疗控制症状的脑转移患者,且未接受过针对靶脑病灶的局部治疗。
- 治疗方案:每21天周期第1天静脉给予卡瑞利珠单抗200 mg、培美曲塞500 mg/m2和卡铂曲线下面积5,共4周期,随后每21天维持卡瑞利珠单抗200 mg和培美曲塞500 mg/m2直至疾病进展、不可耐受毒性或死亡。
- 主要终点为根据改良实体瘤疗效评价标准1.1版确认的颅内客观缓解率,主要在疗效分析集(EAS)中分析。
- 全分析集45例,疗效分析集40例(至少有一次基线后肿瘤评估)。
主要发现
- 截至2022年8月30日,中位随访时间12.5个月(95%CI:9.2-17.3)。
- 疗效分析集确认颅内客观缓解率为52.5%(95%CI:36.1-68.5),全分析集为46.7%(95%CI:31.7-62.1)。
- 疗效分析集颅外客观缓解率为47.5%(95%CI:31.5-63.9),全分析集为42.2%(95%CI:27.7-57.8)。
- 中位颅内无进展生存期7.6个月(95%CI:4.6-未达到),中位总无进展生存期7.4个月(95%CI:4.4-未达到),中位总生存期21.0个月(95%CI:15.9-未达到)。
- 最常见的≥3级治疗相关不良事件为中性粒细胞计数减少6例(13.3%)和贫血4例(8.9%);发生1例治疗相关死亡,原因为免疫相关性肺炎。
关键数值与推荐
- 颅内确认客观缓解率:疗效分析集52.5%(95%CI:36.1-68.5),全分析集46.7%(95%CI:31.7-62.1)。
- 颅外客观缓解率:疗效分析集47.5%(95%CI:31.5-63.9),全分析集42.2%(95%CI:27.7-57.8)。
- 中位颅内无进展生存期7.6个月(95%CI:4.6-未达到),中位总无进展生存期7.4个月(95%CI:4.4-未达到),中位总生存期21.0个月(95%CI:15.9-未达到)。
- ≥3级治疗相关不良事件:中性粒细胞计数减少6例(13.3%),贫血4例(8.9%)。
- 认知功能与生活质量改善趋势:蒙特利尔认知评估p=0.025,肺癌治疗功能评估量表p<0.001。
临床怎么用
- 作者认为,卡瑞利珠单抗联合培美曲塞和卡铂一线治疗非鳞状非小细胞肺癌伴脑转移患者具有活性、毒性可控,并改善认知功能与生活质量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Systemic treatment options for NSCLC with brain metastases (BMs) are scarce. We evaluated the activity and safety of camrelizumab plus chemotherapy as first-line therapy in patients with advanced nonsquamous NSCLC with BMs. METHODS: This was a multicenter, single-arm, phase 2 trial (NCT04211090) conducted at seven hospitals in China. Eligible patients had treatment-naive metastatic nonsquamous NSCLC and BMs that were asymptomatic or symptoms controlled with dehydration therapy and no previous systemic treatment or local therapy for the target brain lesion. Patients received camrelizumab (200 mg) plus pemetrexed (500 mg/m2) and carboplatin (area under the curve 5) intravenously on day 1 of each 21-day cycle for four cycles, followed by maintenance with camrelizumab (200 mg) and pemetrexed (500 mg/m2) every 21 days until disease progression, unacceptable toxicity, or death. The primary end point was confirmed intracranial objective response rate according to modified Response Evaluation Criteria in Solid Tumors version 1.1, which was primarily analyzed in the efficacy analysis set (EAS). RESULTS: A total of 45 patients were enrolled and treated (full analysis set), with 40 patients having at least one post-baseline tumor assessment (EAS). As of August 30, 2022, median follow-up duration was 12.5 months (95% confidence interval [CI]: 9.2-17.3). The confirmed intracranial objective response rate was 52.5% (95% CI: 36.1-68.5) in EAS and 46.7% (95% CI: 31.7-62.1) in full analysis set. The extracranial objective response rate was 47.5% (95% CI: 31.5-63.9) and 42.2% (95% CI: 27.7-57.8), respectively. Median intracranial progression-free survival was 7.6 months (95% CI: 4.6-not reached [NR]), median overall progression-free survival was 7.4 months (95% CI: 4.4-NR), and median overall survival was 21.0 months (95% CI: 15.9-NR). The most common treatment-related adverse events of grade 3 or higher were neutrophil count decrease (six [13.3%]) and anemia (four [8.9%]). One treatment-related death occurred owing to immune-related pneumonia. Linear mixed-effects model displayed that a positive trend for improvement in cognitive function and quality of life was observed based on Montreal Cognitive Assessment and Functional Assessment of Cancer Therapy-Lung scores (p = 0.025, p < 0.001). CONCLUSIONS: Camrelizumab plus pemetrexed and carboplatin was found to have an activity with manageable toxicity and to improve cognitive function and quality of life for patients with nonsquamous NSCLC with BMs in the first-line setting.
引用
- Hou X, Zhou C, Wu G, et al. Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study. J Thorac Oncol. 2023. PMID: 36738928. doi:10.1016/j.jtho.2023.01.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。